News

EFSA publishes GMO data
Enlarge image

RegulatoryEUFranceItaly

EFSA publishes GMO data

17.01.2013 - In the controversy over the harmlessness of GM maize, the EU food watchdog EFSA has published all data from its safety assessment of Monsanto’s NK603.

The EFSA’s move was triggered by „the level of public interest“ after Caen-based researcher Gilles-Eric Séralini claimed Monsanto’s GM maize NK603 harmed the health of lab rats in an experimental setting last September. However, researchers all over the world challenged Seralini’s findings saying his data were insufficient and would require publication of the raw data. 

Up to now, the scientific head of the GMO-sceptic organisation Criigen refused to do so. But in a press conference at the European Parliament Séralini announced he will publish his data now as the EFSA opened up its data first.  The EFSA, which reviews the use and authorisation of GM crops and foodstuffs, in November rejected a report by Seralini which linked NK603 to cancer found in laboratory rats as failing to meet “acceptable scientific standards.“ The EFSA decision is part of a major initiative designed to facilitate access to data, enhancing transparency in risk assessment. “Risk assessment is an evolving science and EFSA is always willing to review its past work should new robust science bring a new perspective to any of the Authority’s previous findings, „ said EFSA chief Catherine Geslain-Lanéelle.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/efsa-publishes-gmo-data.html

BusinessUK

03.03.2015 After weeks of speculation, AstraZeneca has announced its plans to spin out its early-stage antibiotic R&D. The decision marks the company’s aims to “sharpen its focus on three main therapy areas”.

GenericsEUUKHungaryGermanyItalyGreeceAustriaLuxembourgFranceSpain

26.02.2015 It is the first biosimilar monoclonal antibody in many European markets: Mundipharma and Hospira are launching Celltrion’s Remicade generic.

M&AUK

23.02.2015 British drug developer Heptares has been acquired by Japanese biopharma play Sosei for US$400m (€352m).

bioethanolGermanyUKBelgiumFrance

19.02.2015 The price of oil has been sliding for months, and the European bioethanol market is taking it hard. CropEnergies AG has now stopped production at its British unit Ensus UK.

BusinessFranceGermany

17.02.2015 After Christopher Viehbacher’s unceremonious ousting last year, Sanofi has been on the look out for a new CEO. Now, sources say Bayer’s Olivier Brandicourt is set to fill the position.

BusinessUKSwitzerland

12.02.2015 Glaxosmithkline is intent on bolstering its vaccine portfolio further and has bought all shares of Swiss development partner Glycovaxyn.

InvestmentsUKEU

10.02.2015 Interest in biotechnology is on the rise among British investors. Not just one, but two major financiers are planning investment funds in the field.

IVFUKEU

04.02.2015 In a historic move, the UK is set to become the first country to allow the creation of babies with the genetic material of three people – a mother, a father and a female mitochondrial donor.

Events

All Events

Partner-Events

Planegg/Martinsried

1st Munich Biotech Pitch

Berlin (DE)

Proteomic Forum 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MEDIGENE4.64 EUR7.16%
  • FORMYCON16.89 EUR4.07%
  • BIOFRONTERA1.99 EUR3.65%

FLOP

  • HBM102.00 CHF-2.86%
  • SYNGENTA327.00 CHF-2.15%
  • STRATEC BIOMEDICAL45.12 EUR-2.10%

TOP

  • WILEX3.17 EUR47.4%
  • EVOLVA1.70 CHF18.9%
  • MEDIGENE4.64 EUR16.0%

FLOP

  • MOLOGEN5.25 EUR-12.5%
  • SANTHERA98.45 CHF-10.2%
  • 4SC0.77 EUR-9.4%

TOP

  • SANTHERA98.45 CHF2417.9%
  • WILEX3.17 EUR395.3%
  • FORMYCON16.89 EUR119.4%

FLOP

  • CYTOS0.37 CHF-86.9%
  • MOLOGEN5.25 EUR-56.0%
  • PAION2.10 EUR-52.5%

No liability assumed, Date: 03.03.2015